Antiarrhythmic drugs in pregnancy
Jennifer M Wright1, Richard L Page1, Michael E Field1
1a Cardiovascular Division, Department of Medicine , University of Wisconsin School of Medicine and Public Health , Madison , WI , USA.
Expert Review of Cardiovascular Therapy
|October 30, 2015
Summary
Pregnancy increases arrhythmia risks. For persistent or high-risk cases, medical treatments are available, balancing maternal and fetal safety with therapeutic benefits.
Area of Science:
- Cardiology
- Maternal-Fetal Medicine
- Pharmacology
Background:
- Pregnancy is associated with an elevated risk of cardiac arrhythmia development and recurrence.
- Conservative management strategies like vagal maneuvers and lifestyle changes may not always be effective for managing arrhythmias during pregnancy.
Purpose of the Study:
- To review the available therapeutic options for managing cardiac arrhythmias during pregnancy.
- To emphasize the importance of risk-benefit assessment for pharmacological interventions in pregnant patients with arrhythmias.
Main Methods:
- Literature review of studies on antiarrhythmic drug safety and efficacy in pregnancy.
- Analysis of clinical guidelines and case reports concerning pregnancy-related arrhythmias.
Main Results:
- While some antiarrhythmic drugs have extensive safety data in pregnancy, others have limited information.
- Therapeutic options exist for managing arrhythmias in pregnant individuals, but require careful consideration.
Conclusions:
- Medical therapy for arrhythmias during pregnancy is sometimes necessary when conservative measures fail or when risks are high.
- Informed decision-making regarding antiarrhythmic drug use in pregnancy necessitates a thorough understanding of both safety and efficacy profiles.
Related Concept Videos
01:22Antiarrhythmic Drugs: Class I Agents as Sodium Channel Blockers
4.1K
Class I antiarrhythmic drugs are used to treat various types of arrhythmias or irregular heart rhythms. These drugs block the sodium (Na+) channels in the cardiac cells, thereby affecting the movement of electrical impulses across the heart. Class I antiarrhythmic drugs are divided into three subgroups: Class IA, Class IB, and Class IC, each with distinct mechanisms of action and effects on the heart.
Class 1A Antiarrhythmic Drugs: These drugs work by moderately blocking sodium channels,...
Class 1A Antiarrhythmic Drugs: These drugs work by moderately blocking sodium channels,...
4.1K
01:12Antiarrhythmic Drugs: Class III Agents as Potassium Channel Blockers
2.9K
Class III antiarrhythmic drugs are a group of medications that can prolong action potentials in the heart. They achieve this by blocking potassium channels or enhancing inward currents from sodium channels. However, these drugs have a unique property of "reverse use-dependence," which is most pronounced at slower heart rates and can lead to torsades de pointes—a specific type of arrhythmia. However, it is essential to note that excessive QT interval prolongation—a measure of...
2.9K
01:24Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers
2.3K
Adrenergic stimulation generally impacts cardiac rate and rhythm. Specifically, stimulation of the β-adrenoceptors triggers an increase in intracellular calcium ion influx and pacemaker currents, which may cause arrhythmias. Catecholamines like adrenaline also demonstrate β2-adrenoceptor-mediated hypokalemia, impacting cardiac action potential and disrupting the normal cardiac rhythm. Class II antiarrhythmic drugs are β-adrenoceptor antagonists or β-blockers, which...
2.3K
01:20Antiarrhythmic Drugs: Class IV Agents as Calcium Channel Blockers
2.6K
Class IV antiarrhythmic drugs, such as verapamil and diltiazem, block calcium channels. They primarily affect the heart, slowing the conduction in calcium-dependent tissues like the SA and AV nodes. These drugs manage reentrant supraventricular tachycardia (SVT) and reduce ventricular rate in atrial flutter/fibrillation.
Verapamil, a calcium channel blocker, inhibits calcium movement across myocardial cell membranes and vascular smooth muscle. This results in the dilation of coronary and...
Verapamil, a calcium channel blocker, inhibits calcium movement across myocardial cell membranes and vascular smooth muscle. This results in the dilation of coronary and...
2.6K
01:25Dysrhythmias VI: Management of Dysrhythmias
615
Dysrhythmia management involves a multifaceted approach, incorporating pharmacological treatments, medical procedures, surgical interventions, lifestyle modifications, and patient education.Pharmacological ManagementAntiarrhythmic Drugs:Class I (Sodium Channel Blockers): This class includes quinidine and procainamide, which reduce the speed of impulse conduction in the heart, stabilize the cardiac membrane, and control arrhythmias. Quinidine and procainamide are Class IA agents that prolong the...
615
01:31Adrenergic Antagonists: ɑ and β-Receptor Blockers
1.4K
Third-generation β-blockers, such as labetalol and carvedilol, represent a significant advancement in managing cardiovascular conditions. Unlike conventional β-blockers, which can induce peripheral vasoconstriction, third-generation drugs block α1 adrenoceptors. This promotes vasodilation through several mechanisms, such as increased nitric oxide production, inhibition of calcium ion entry, opening of potassium ion channels, and antioxidant action. Labetalol, for instance, is...
1.4K